Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
What does it do?
Boston Scientific makes the medical tools that doctors use inside your body without major surgery. Think of tiny devices threaded through a catheter — a thin flexible tube — to fix a leaky heart valve, stop internal bleeding, or blast a kidney stone without making a large incision. Their SpyGlass scope, for example, lets a doctor look directly inside a bile duct using a camera smaller than a pen tip. They sell these tools to hospitals in over 100 countries.
Boston Scientific is one of the few medical device companies large enough to compete in both heart procedures and digestive-system surgeries at the same time, giving it rare pricing power with hospital networks. Revenue jumped from $16.7B to $20.1B in a single year — a 20% increase — which is unusually fast growth for a company this size. With aging populations in the US, Europe, and Asia driving demand for minimally invasive procedures, the market it sells into is structurally expanding.
How does it make money?
Boston Scientific makes money by selling single-use and reusable medical devices to hospitals, surgical centers, and clinics. Its two segments are MedSurg — covering digestive, urological, and respiratory tools — and Cardiovascular, which includes heart rhythm devices, stents, and structural heart repair products. The company generated $20.1B in revenue last year and $2.9B in net profit, meaning it kept about 14 cents of profit for every dollar of sales. Most devices are consumables, meaning hospitals keep reordering them after each procedure, creating a reliable, recurring revenue stream.
Why do investors care?
The core growth story is simple: more people are getting older, more hospitals want less invasive procedures, and Boston Scientific makes the tools that make that possible. The company has been aggressively acquiring smaller innovators — it bought Axonics in 2024 for roughly $3.7B to strengthen its position in bladder control devices. For the thesis to work, it needs to keep integrating acquisitions smoothly, hold off competition from Medtronic and Abbott, and continue expanding in faster-growing markets like China and India.
Deep Dive
MemberA full investor briefing on Boston Scientific Corporation — history, leadership, risks, and outlook.